The Employee Benefit Research Institute (EBRI) today released a new report, “Cell and Gene Therapies in Employment-Based Health Insurance: Financing the High-Cost, High-Impact Future,” finding that use of cell and gene therapies in employer health plans remains rare — 9.2 per 100,000 in 2022 — but is rising gradually, and costs are concentrated among a small share of claimants.
Cell and gene therapies (CGT) are a rapidly advancing frontier in medicine, offering the potential to treat — and in some cases cure — serious conditions, such as sickle cell disease and hemophilia, by targeting diseases at the cellular or genetic level. While it can be transformative for patients, CGT is among the highest-cost treatments in health care. As approvals continue and the pipeline expands, employers and plan sponsors may face growing financial risk.
Using claims data, EBRI analyzed the prevalence of conditions targeted by cell and gene therapies, utilization patterns and spending among users, highlighting how costs can be concentrated among a small subset of high-cost claimants and what that may mean for plan financing and benefit design.
Key findings in the new research report include:
• Rising Number of Approvals: As of 2025, the U.S. Food and Drug Administration has approved 48 CGTs, with more in development. A growing number of these therapies are targeting conditions that are more common than traditional rare diseases. While utilization remains limited, the expanding pipeline suggests employers may need to prepare for broader financial exposure in coming years.
• Modest Growth in Use: Use of CGTs remains limited but has shown a gradual increase. In 2018, 7.9 per 100,000 enrollees received a CGT; by 2022, the rate rose to 9.2 per 100,000.
• Small Share of Spending: CGT users represent fewer than 0.1% of the enrollee population but account for approximately 0.5% of total spending. This includes both the cost of CGTs and spending on other health services. These proportions remained relatively stable between 2018 and 2022.
• Impact on High-Cost Claimants: Among enrollees in the top 1% of total health care spenders, just 0.58% used CGTs. However, these individuals accounted for 1.6% of spending within that top spending group. While the share is small, it signals that CGTs can meaningfully impact spending patterns among high-cost claimants.
“Cell and gene therapies remain uncommon in employment-based plans today, but the trajectory matters. Our analysis shows utilization rising gradually and spending concentrated among a small share of high-cost claimants — signals that employers, insurers, and policymakers should begin testing financing and payment models now to preserve access while managing risk as the CGT pipeline expands,” said Paul Fronstin, director, Health Benefits Research, EBRI.
Why it matters for employers and plan sponsors
The EBRI analysis notes that traditional cost-sharing tools (such as deductibles and out-of-pocket maximums) may have limited influence on utilization among the highest-cost claimants, including those receiving CGTs. Employer size also shapes risk management: Larger self-insured employers can spread risk more easily across a bigger covered population, while smaller employers may be more exposed and often rely on stop-loss insurance — an approach that can have limitations, including exclusions for known high-cost individuals. For smaller self-insured employers, even a single $1 million claim can represent a double-digit share of annual health spending.
To manage CGT-related financial exposure, employers and insurers are exploring approaches such as stop-loss insurance, carve-out programs, gene therapy reinsurance, value-based payment arrangements, performance-based contracts, amortization, and other risk-spreading mechanisms. The EBRI study also notes that many of these strategies are promising but remain largely unproven at scale for CGTs, making continued evaluation essential.
0.58% used CGTs. HoweNe ver w , th s Fr ese om ind The ividu Emp als ac loyee Be countn ed efit for R 1.6 ese% of arch I spe nsti nd tut ing e within that top spending group. While the share is small, it signals that CGTs can meaningfully impact spending paEmplo tterns am yee ong Bene high fit - R ce os se t ar claima ch Ins nti ts. tut e Study Finds Cell and Gene Therapy Use Remains Rare but Rising Slowly in Employer Health Plans “Cell and gene therapies remain uncommon in em ployment-based plans today, but the trajectory matt N er ew r s. O esear ur anc aly h u si ses c s sho laims ws utiliz data a tion to ex ris am ing ine gr u ad tiliz ually an ation,d spe spe nn dd ing ing an conc d sten rat tr eg at ies ed em amp ong loyer a s ar small e share of high-cost claimants — signals t explorh ing at t em o m plo an yag ere s, fina insu nrc er ial risk s, and policymakers should begin t esting financing and payment models now to preserve access while managing risk as the CGT p For ipe im line m ed expan iate d rs, ele ” sa ase: id P Feb aul . Fr 19 ons , 20 tin 26 , director, Health Benefits Research, EBRI. For more information: Ron Dresner d Wh resn y it er@eb matter ri.or s for g employers and plan sponsors The EBRI analysis notes that traditional cost-sharing tools (such as deductibles and out-of-pocket m (W aashin ximum gts) on, mD a.y Ch .)a – v e Th limit e Em ed p lo influ yee en Bc en e e ofit n u R tiliz esear ation ch Iam nstit ong ute th (EBR e high I) tes oda t-c y os rele t claima ased a nts, new inc rlud epor ing t, th “Ce os ll an e rec d eivin Gene g Th CG e T rs. ap Em ies pin loy Em er p siz loe ym als en o s t-h Bap ased es ris Health k man In ag sur emen ance: t: Fi Lar nan ger cing self th -insu e Hig red h- C em osp t,lo High yers - c Im an p ac spr t ead Futu ris re, k ” findi more n easily a g that u cse ross of a cell bigan ger d c go en ver e ed ther popu apies lation, in em while ployer smalle healtr e h p m lan plo s r yem ers m ain a s r y b ar e e — m 9.2 orp e er expos 100,ed 00 0 an in d 2 o0 ft 22 en — rely buon t is ris stop ing -lo gr ssad insu ually ran , c an e d — c os ants ap ar pe conc roach en tha tr t ac tan ed h am avong e lim a itsmall ations, share of c inc laima luding nts. e xclusions for known high-cost individuals. For smaller self-insured employers, even a single $1 million claim can represent a double-digit share of annual health spending. Cell and gene therapies (CGT) are a rapidly advancing frontier in medicine, offering the potential to T tr o m eat an —ag an e d C in GT so -rela me cases ted finacn ucrial e e —xpos serio uu re s , cem ond pitions loyers an , suc dh insu as si rer ckle s ar ce ell ed xplor isease ingan ap d p h roach emoph es ilia, such b as y t sar top geti -lon sg s in disease suranc se, at cth are ve c-ellu out lar or g program ens, eti gc en lev e el. Wh therapile y rit ein can sur b ae nc tr e, an valu sfor em -ba ased tive fp or aym paen tiet nts, CGT is am arran ong gem the en hts, ighp eerf st-or cos m t an trea cetm -based ents c in he ontrac alth ts, cam are. As ap ortization, pro v an als d c othe ontin r risk ue an -spr d t ead he pip ing elin mec e he an xpan isms. ds, em The pEBR loyer I s s an tudd y p also lan n sp ot onso es th rs m at m aan y fy ac of e gr tho ese win sg trfina ateg nies cial risk. are pr omising but remain largely unproven a t scale for CGTs, making continued evaluation essential. Using claims data, EBRI analyzed the prevalence of conditions targeted by cell and gene therapies, T uo r tiliz ev ation iew th pa e tt n ern ew s an resear d spe chn rd ep ing or am t, vis ong it hu ttp ser s:// s, h ww ighw ligh .eb tin ri.g or h g o /w c pub os lica ts tions/r can be esear concc en h-trated among a p small ublica sub tions/is set ofsue high -b-ri ce os fs/ t c claima onten n t/ ts cell an-d an wh d-g aen t th ea -th t m er a ap y m ies ean -in-f em or p plo lan ym fina ent n -c bing ased an -h deal ben the -fit insu design rance.-- financing-the-high-cost--high-impact-future. K ey findings in the new research report include: The Employee Benefit Research Institute is a nonprofit, independent and unbiased research or • Ris gan in izg a tion Numth ber at of pro A vide ppro s t va hls e : m As os o t f 2 au02 thor 5, it th ae tiv U e .S. an Fd oo objec d antiv d Drug e infor Adm mainis tion trab ation out h ca ritic s ap al pis ro sue ved s 48 C rela GTtin s, wi g t th o e m m or pe loin yee dev ben elopm efit p en rogr t. A g am rs in owi n th g e nUn um it b ed er St ofa th tes. ese Th th e er or ap gan ies iza ar tion e tar also geti c no g or cond dina itions tes that ac are tivitie more s fc or omm the on Cen th te an r f tr or ad Ritional esearch rar on e d He iseases. alth Ben Wh efits I ile un tiliz noa va titi on on, rem Fin ain ans lim cial W ited ellb , t ein he g eR xpan esear ding ch C pipe entline er an sug d R geti ests rem emplo ent Sec yeru s m rity ay Resear need c th o p Cen rep ter are an for d p brrodu oade ces r fina a variety ncial eo xpos f lead uring e in com indusing try y sur eav rs. ey s d uring the year. For more information, visit www.ebri.org. • Modest Growth in Use: Use of CGTs remains limited but has shown a gradual increase. In 2018, 7.9 per 100,000 enrollees received a CGT; by 20 # 22 , th e # rate rose to 9.2 per 100,000. • Sm( al ME l SDIA N hare of OTE: Spe T ndi o rec ng: ei C vG e an T ud r sere s r vie ep w resen the c t omple fewer tth e r an es 0.1% earch r ofepo the ren t, emai rollee l R pon Dr opulaes tion ner b u at t account for approximately 0.5% of total spe dres nn der ing @ . Th ebri.or is incg lud ). es both the cost of CGTs and spending on other health services. These proportions remained relatively stable between 2018 and 2022. • Impact on High-Cost Claimants: Among enrollees in the top 1% of total health care spenders, just